A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study

Fernando de Andrés-Nogales1 · Miguel Ángel Casado1 · José Luis Trillo2 · José María Ruiz-Moreno3,4 · José Manuel Martínez-Sesmero5 · Gemma Peralta6 · José Luis Poveda7 · Pere Ortiz8 · Emilio Ignacio9 · Javier Zarranz-Ventura4,10 · Patricia Udaondo7 · Carlos Mur11 · Eloisa Álvarez5 · Enrique Cervera12 · Mercedes Martínez13 · Iñaki Llorente14 · Jacinto Zulueta15 · Mariano Rodriguez-Maqueda16 · Alfredo García-Layana4,17 · José Martínez-Olmos18

Published online: 25 February 2020 © The Author(s) 2020

Abstract

Background The clinical and economic management of retinal diseases has become more complex following the introduction of new intravitreal treatments. Multicriteria decision analysis (MCDA) offers the potential to overcome the challenges associated with traditional decision-making tools.

Objectives A MCDA to determine the most relevant criteria to decision-making in the management of diabetic macular edema (DME) based on the perspectives of multiple stakeholders in Spain was developed. This MCDA was termed the MULTIDEX-EMD study.

Methods Nineteen stakeholders (7 physicians, 4 pharmacists, 5 health authorities and health management experts, 1 psychologist, and 2 patient representatives) participated in this three-phase project. In phase A, an advisory board defined all of the criteria that could influence DME treatment decision-making. These criteria were then screened using a discrete choice experiment (DCE) (phase B). Next, a multinomial logit model was fitted by applying the backward elimination algorithm (relevant criteria: \( p \) value < 0.05). Finally, the results were discussed in a deliberative process (phase C).

Results Thirty-one criteria were initially defined (phase A) and grouped into 5 categories: efficacy/effectiveness, safety, organizational and economic impact, patient-reported outcomes, and other therapeutic features. The DCE results (phase B) showed that 10 criteria were relevant to the decision-making process for a 50- to 65-year-old DME patient: mean change in best corrected visual acuity (\( p \) value < 0.001), percentage of patients with an improvement of ≥ 15 letters (\( p \) value < 0.001), effect duration per administration (\( p \) value = 0.008), retinal detachment (\( p \) value < 0.001), endophthalmitis (\( p \) value = 0.012), myocardial infarction (\( p \) value < 0.001), intravitreal hemorrhage (\( p \) value = 0.021), annual treatment cost per patient (\( p \) value = 0.001), health-related quality of life (HRQoL) (\( p \) value = 0.004), and disability level (\( p \) value = 0.021).

Conclusions From a multi-stakeholder perspective, the selection of an appropriate treatment for DME patients should guarantee patient safety and maximize the visual acuity improvement and treatment effect duration. It should also contribute to system sustainability by being affordable, it should have a positive impact on HRQoL, and it should prevent disability.

1 Introduction

Decision-making in healthcare is a highly complex process for stakeholders due to the presence of multiple factors and differing objectives that can influence the selection of a treatment or health intervention. To make optimal decisions, there is a need to integrate and prioritize all relevant criteria. In addition to considering clinical efficacy and safety variables, there are other clinical and nonclinical factors that can influence treatment selection, such as costs, efficiency, budgetary availability, patient-reported outcomes, and adherence to and persistence with treatment. Bypassing a formal decision-making process can result in variability, inconsistency, and a lack of transparency, which could lead to suboptimal decisions [1]. This process becomes even more complicated when the opinions of stakeholders from different fields are taken into account, such as the clinical, psychological, clinical management, health administration, and patient perspectives.
Multicriteria decision analysis (MCDA) offers the potential to overcome the challenges associated with traditional decision-making tools, especially for complex decisions that must consider multiple criteria, simultaneously evaluate quantitative and qualitative information, and involve multiple stakeholders [2]. MCDA comprises a broad set of techniques that have been applied in various areas within and outside of the health sector and facilitate a rigorous approach to decision-making in complex environments. MCDA helps to increase the consistency and transparency of these decisions. The techniques used in MCDA divide the decision-making process into different stages in a structured way and explicitly incorporate the preferences of the participants in the process (stakeholders and influencers), thus providing clarity on the relevant criteria and their relative importance [1, 2].

Diabetic macular edema (DME) is an ocular complication of diabetes mellitus. This disorder involves the accumulation of fluid in the central portion of the retina as a consequence of the failure of the blood–retinal barrier [3]. This affects the sensitivity of the macular photoreceptor cells, leading to changes in vision and vision loss [4]. DME is the leading cause of visual impairment and blindness in people with diabetes [5], and its incidence in Spain has increased in recent years [6], similar to the incidence of diabetes. Currently, pharmacological management of DME consists of administering corticosteroids or antiangiogenic drugs by intravitreal injection [3].

The arrival of new intravitreal treatments for retinal diseases has increased the complexity of clinical and economic management in ophthalmology. Sustainability challenges have appeared as a result of the much higher costs of the new treatments and the organizational impact of intravitreal administration. MCDA could aid decision-making in this environment, as it takes the perspectives of the different stakeholders into consideration.

The objective of this work was to determine the most relevant criteria for decision-making in the treatment of DME patients by considering the perspectives of all the stakeholders involved in this decision: physicians, hospital pharmacists, psychologists, experts in health management, local and national health authorities, and patient associations.

### 2 Methods

MCDA for the management of patients with DME was carried out according to the recommendations of The Professional Society for Health Economics and Outcomes Research (ISPOR), which defines the techniques that can be used and the phases to be followed throughout a MCDA [1, 7].

This MCDA, which was termed the MULTIDEX-EMD study, was performed in three phases: an initial phase (phase A), where the criteria most relevant to the decision-making process in the treatment of DME were defined and selected; phase B, where the criteria were screened, weighted, and prioritized; and phase C, where the results were discussed and the conclusions of the project were established in a deliberative process. This study was carried out from February to May 2018 (Fig. 1).

Twenty participants were selected to develop the whole project. They were chosen based on their influence on healthcare decision-making at different levels and/or specific involvement with the disease. Four groups of stakeholders who were from different fields and therefore had different perspectives on DME-related decisions were identified: clinical (7 physicians: 6 ophthalmologists specializing in retinal and vitreous disease and 1 endocrinologist), health management and health administration (3 representatives/former health authority representatives at national or regional levels, such as the Ministry of Health and Regional Health departments, and 3 health management experts representing medical management or hospital management positions and the academic field of health management and quality), hospital pharmacy (4 pharmacists), and the patient’s perspective (2 members of patient associations and 1 clinical psychologist specializing in the management of people with diabetes). Invitations were sent out to determine the availability and willingness to participate of the experts initially selected. Because some of those experts were unavailable, additional experts were invited to participate until the required number of participants was reached. A breakdown of the participants involved in each phase of the study is shown in Fig. 1.
2.1 Phase A: Defining the Criteria and Their Levels

This phase aimed to define the criteria of interest for decision-making in the management of a patient with DME and to establish the design of the subsequent analysis from these relevant criteria. A panel of experts was established; this panel then selected and defined the criteria.

During this phase, a questionnaire was developed that included a set of initially proposed criteria and their definitions. This questionnaire was sent to the participants for review, but it was also possible for participants to propose new criteria. Criteria were initially identified by means of a bibliographic review that included clinical trials of the options available, disease burden studies, and health technology assessment reports that were available for this pathology. Criteria that characterized a DME treatment were selected, such as efficacy, safety, costs, organizational impact, and economic impact. When identified criteria were similar, the more frequently used and comprehensive criterion was selected to avoid duplication. Clinical and safety criteria were generally obtained from clinical trials, and focused on the main endpoints assessed in these studies. Each of the criteria had two or more possible levels; these levels characterize the criterion. After completing the questionnaire, the panel of experts had a face-to-face meeting aimed at reaching a consensus regarding the final criteria and their levels. The selected criteria served as the basis for the next phase of the study.

2.2 Phase B: Screening and Weighting the Criteria

The main objective of this phase was to screen the criteria that were truly relevant to decision-making and to rank them by weighting their relative importance according to the preferences of the participating stakeholders. This prioritization process was performed in reference to the case of a 50- to 65-year-old diabetic patient with DME.

To obtain the preferences of the participants, the discrete choice experiment (DCE) method was used, which was implemented according to international good practice recommendations [8, 9]. An electronic questionnaire was administered to 19 stakeholders (Fig. 1). The questionnaire was designed based on the combination of the criteria and levels selected in phase A and consisted of several questions or items. Each item comprised a pair of hypothetical treatments characterized by a unique combination of criteria levels.

For each item, the participants were asked to choose which of the two hypothetical treatments was the best option based on their preferences. The minimum necessary number of items (i.e., pair of hypothetical treatments) to establish the relevance of the criteria with sufficient statistical significance was generated. For this purpose, an orthogonal design was chosen using the “Support.CEs” package [10]. This design was chosen due to a lack of prior information about whether there is a tendency of avoidance or preference towards the criteria. This design implies that each criterion level is compared with the rest of the criteria levels equally or proportionally.
To facilitate the completion of the questionnaire, the items were divided into several blocks, which generated four different questionnaires to be completed by the stakeholders.

After obtaining the answers to the questionnaires, two statistical analyses were carried out by fitting multinomial logit models—one to screen the criteria according to their relevance and the other to estimate the weights. The backward elimination algorithm was used to fit the general model used to screen the criteria. This algorithm was based on a complex general model (with a large number of criteria), and it sequentially eliminated the criteria with the largest \( p \) values until all of the criteria included in the model had statistically significant \( p \) values (\( p < 0.05 \)). A second multinomial logit model was then fitted to estimate the weights of the screened criteria.

The relative importance index was used to weight the criteria:

\[
WD_i = \frac{\max(\beta_{Di}) - \min(\beta_{Di})}{\sum_{D1}^{Dn} \left[ \max(\beta_{Di}) - \min(\beta_{Di}) \right]} \times 100,
\]

where \( \beta_{Di} \) is the estimator domain \( i \) and \( WD_i \) is the percentage of weight domain \( i \).

All statistical analyses were performed using R software (version 3.2.3, R Foundation for Statistical Computing, Vienna, Austria) [11].

After analyzing the answers to the questionnaires, the model that best predicted the decision-making process was established by selecting the most relevant criteria. In this model, each criterion was weighted based on the choice preferences of the participants.

### 2.3 Phase C: Deliberative Process

The final phase of the MCDA involved presenting the results and discussing and interpreting the screened criteria and their weights according to the preferences of the participants. The conclusions of the analysis were also established during this phase through a face-to-face meeting involving 12 of the stakeholders from the panel of experts (Fig. 1). The comments and conclusions that emerged from this meeting about the study and the respective results are included in Sect. 4 below.

### 3 Results

#### 3.1 Defining the Criteria and Their Levels

In phase A, after the initial meeting, the panel of experts established and defined a total of 31 possible criteria that could be relevant in the management of patients with DME. These criteria and their levels are detailed in Table 1. Throughout the study, the criteria were divided into five categories to help the participants to manage them in a more structured way, considering the large number of criteria involved. However, the criteria were considered independently, and the importance of each criterion was weighted individually. The categories were efficacy/effectiveness, safety, organizational and economic impact, patient-reported outcomes (patient and caregiver), and other therapeutic features. By combining the levels of the 31 selected criteria, a set of 120 pairs of hypothetical treatments corresponding to the items of the DCE questionnaire were obtained using an orthogonal design.

#### 3.2 Criteria Screening

The results of the DCE indicated that 10 of the 31 criteria were considered relevant to decision-making in the management of a 50- to 65-year-old diabetic with macular edema (Table 2). In the fitted logit model, three of the seven efficacy/effectiveness criteria (those related to visual acuity and duration of effect) were statistically significant according to the analysis. Of the eight safety criteria selected, four were relevant (three ocular adverse events and one systemic adverse event). In relation to the patient-reported outcomes provided by the patient and/or caregiver, two of the five criteria were relevant (health-related quality of life and disability). Finally, only one (annual pharmaceutical cost per patient) of the six criteria relating to the organizational and economic impact established in phase A was statistically significant in the analysis.

#### 3.3 Criteria Weighting

The screened criteria that had statistically significant coefficients were fitted using a logit model to estimate the weight of each criterion that was relevant to the decision-making process for the management of DME patients. Figure 2 shows the relative weight of each criterion. The considered criteria relating to safety constituted 47% of the overall weight in decision-making, and 35% when all the efficacy/effectiveness criteria were considered. The criteria concerning patient-reported outcomes accounted for 11% of the total weight, and the criterion associated with organizational and economic impact comprised 7% of the overall weight.

The most relevant criterion for decision-making in the treatment of patients with DME was the mean change in best corrected visual acuity (BCVA) (5-letter improvement), pertaining to efficacy (weight: 17%). This was followed by adverse event criteria such as retinal detachment (16%) and acute myocardial infarction (13%). Another efficacy-related criterion with a high weight was a \( \geq 15 \) letter improvement in BCVA (12%). The remaining criteria had weights of less than 10%.
Table 1  List of selected criteria for decision-making in diabetic macular edema management

| Criteria                                                                 | Levels                                                                 |
|------------------------------------------------------------------------|------------------------------------------------------------------------|
| **Efficacy/effectiveness**                                              |                                                                        |
| Mean change in BCVA (5-letter improvement)                             | 0–5 letters                                                             |
|                                                                        | 6–10 letters                                                             |
|                                                                        | 11–15 letters                                                            |
|                                                                        | > 15 letters                                                              |
| ≥ 15 letter improvement in BCVA                                       | 0–15% patients                                                          |
|                                                                        | 16–30% patients                                                          |
|                                                                        | > 30% patients                                                            |
| Reduction in central retinal thickness                                 | ≤ 20% reduction                                                          |
|                                                                        | > 20% reduction                                                           |
| Speed of action: visual acuity improvement                             | < 1 month                                                                |
|                                                                        | 1–3 months                                                               |
|                                                                        | > 3 months                                                               |
| Effect duration per administration                                     | ≤ 1 month                                                                |
|                                                                        | > 1–4 months                                                             |
|                                                                        | > 4–12 months                                                             |
|                                                                        | > 12 months                                                              |
| Response in patients who were previously treatment refractory         | Response is maintained after change of treatment due to lack of response|
|                                                                        | Response is improved after change of treatment due to lack of response   |
|                                                                        | Response is reduced after change of treatment due to lack of response    |
| Reduction in the need for long-term treatment (3 years)                | Yes                                                                     |
|                                                                        | No                                                                      |
| **Safety**                                                             |                                                                        |
| Ocular adverse events: increased intraocular pressure                  | Occurrence: controlled with medical treatment                           |
|                                                                        | Occurrence: controlled with surgical treatment                           |
|                                                                        | Nonoccurrence                                                            |
| Ocular adverse events: endophthalmitis                                 | Occurrence                                                               |
|                                                                        | Nonoccurrence                                                            |
| Ocular adverse events: retinal detachment                              | Occurrence                                                               |
|                                                                        | Nonoccurrence                                                            |
| Ocular adverse events: vitreous hemorrhage                             | Occurrence                                                               |
|                                                                        | Nonoccurrence                                                            |
| Ocular adverse events: cataract                                         | Occurrence                                                               |
|                                                                        | Nonoccurrence                                                            |
|                                                                        | Progression                                                              |
| Systemic adverse events: acute myocardial infarction                   | Occurrence                                                               |
|                                                                        | Nonoccurrence                                                            |
| Systemic adverse events: cerebrovascular accident                      | Occurrence                                                               |
|                                                                        | Nonoccurrence                                                            |
| **Immunogenicity**                                                     |                                                                         |
|                                                                        |                                                                         |
| **Organizational and economic impact**                                  |                                                                         |
| Budget impact                                                          | Positive (increased costs in the budget)                                |
|                                                                        | Neutral (no increased costs nor cost savings in the budget)             |
|                                                                        | Negative (cost savings in the budget)                                   |
| Annual treatment cost per patient                                      | < €500                                                                  |
|                                                                        | €500–1500                                                                |
|                                                                        | > €1500–3000                                                              |
|                                                                        | > €3000                                                                  |
Discussion

MCDA enables the establishment of a framework that stakeholders can use as a tool to probe the full range of DME treatment existing preferences and to systematize transparent decision-making. In this sense, the present study could serve as the basis for DME treatment selection, ensuring that there is a multistakeholder perspective that covers the criteria that are important to all decision-makers involved, rather than focusing only on the viewpoint of physicians or health authorities/payers. The results of this analysis highlight the overall importance of DME treatment safety to the stakeholders involved in this project; its relevance

Table 1 (continued)

| Criteria | Levels |
|----------|--------|
| Number of intravitreal injections (first year) | ≤ 3 |
| | > 3 |
| Minimum required facilities | Clean room |
| | Surgery room |
| Healthcare burden (need of use of resources, such as visits, injections, or tests) | The treatment implies an increase in the healthcare burden |
| | The treatment does not modify the healthcare burden |
| | The treatment implies a reduction in the healthcare burden |
| Need of pharmacy handling | Pharmacy handling |
| | No pharmacy handling |
| Patient-reported outcomes (patient and caregiver) | Improvement in functional capacity and performance of activities of daily living |
| | No effect on functional capacity and performance of activities of daily living |
| | Worsening of functional capacity and performance of activities of daily living |
| Health-related quality of life | Improvement in quality of life (social/occupational) |
| | No effect on quality of life (social/occupational) |
| | Worsening of quality of life (social/occupational) |
| Effect on emotional state | Anxiety and depression treated pharmacologically |
| | Anxiety and depression treated nonpharmacologically |
| | No anxiety or depression |
| Treatment satisfaction | Improvement |
| | No effect |
| | Worsening |
| Caregiver burden (related to the pharmacological treatment) | No increase in the caregiver burden |
| | Moderate increase in the caregiver burdena |
| | High increase in the caregiver burdenb |
| Other therapeutic features | Persistent patient |
| | Nonpersistent patient |
| Treatment persistence | Modified or delayed release |
| | No modified release |
| Pharmaceutical form | Vial |
| | Syringe/injector |
| | Vial and syringe/injector |
| Available presentations | Yes |
| | No |
| Therapeutic innovation: new mechanism of action | Therapeutic innovation: new therapeutic target |
| | Yes |
| | No |
| | No |

BCVA best-corrected visual acuity

aThe caregiver is occasionally required to accompany the patient during visits relating to pharmacological treatment

bThe caregiver is frequently or always required to accompany the patient during visits relating to pharmacological treatment

4 Discussion

MCDA enables the establishment of a framework that stakeholders can use as a tool to probe the full range of DME treatment existing preferences and to systematize transparent decision-making. In this sense, the present study could serve as the basis for DME treatment selection, ensuring that there is a multistakeholder perspective that covers the criteria that are important to all decision-makers involved, rather than focusing only on the viewpoint of physicians or health authorities/payers. The results of this analysis highlight the overall importance of DME treatment safety to the stakeholders involved in this project; its relevance
Multi-stakeholder MCDA for DME Management

to decision-making accounted for almost half of the total weight across all criteria.

Although currently available treatments are considered very safe from the physician’s perspective, and there is no concern over their use or the management of possible events, the potential for the patient to suffer a serious adverse event could be a determining factor in the choice of treatment when a decision is made considering a broader perspective involving different stakeholders viewpoints. Another important aspect was found to be the efficacy of the therapeutic alternatives. Indeed, the ability to change the BCVA was the most important criterion, mainly because it is directly related to the visual capacity of the patient.

An important and positive aspect of MCDA is that it integrates existing methodologies that are widely used in other fields. Several recommended techniques with different complexities and theoretical foundations can be used to identify preferences, such as the analytic hierarchical process, DCE, and conjoint analysis [1]. DCE is an instrument with a strong theoretical foundation, so, unlike other techniques, it adds considerable robustness to the process of screening and prioritizing the criteria in a MCDA. In this study, criteria selection was based on the available evidence and the

| Table 2 | Results of the adjusted multinomial logit model |
|----------------|---------------------|---------------------|---------------------|
| **Constant**   | 0.07                | 0.109               | 0.64                | 0.522               |
| **Mean change in BCVA (5-letter improvement)** | 0.77                | 0.118               | 6.513               | < 0.001             |
| **≥ 15 letter improvement in BCVA** | 0.53                | 0.102               | 5.213               | < 0.001             |
| **Effect duration per administration** | −0.254              | 0.096               | −2.639              | 0.008               |
| **Ocular adverse events: endophthalmitis** | 0.417               | 0.166               | 2.509               | 0.012               |
| **Ocular adverse events: retinal detachment** | 0.697               | 0.172               | 4.041               | < 0.001             |
| **Ocular adverse events: vitreous hemorrhage** | 0.392               | 0.17                | 2.307               | 0.021               |
| **Systemic adverse events: myocardial infarction** | 0.574               | 0.162               | 3.551               | < 0.001             |
| **Annual treatment cost per patient** | 0.306               | 0.092               | 3.335               | 0.001               |
| **Disability level** | −0.211              | 0.091               | −2.306              | 0.021               |
| **Health-related quality of life** | 0.253               | 0.087               | 2.919               | 0.004               |

| **Log-likelihood** | −253.84               | **McFaddens R²** | −0.202               | **Likelihood ratio test** | 128.452 (10 gl) | p < 0.001 |

BCVA best corrected visual acuity

Fig. 2 Relevant criteria for decision-making in diabetic macular edema management (50- to 65-year-old patient). BCVA best corrected visual acuity
characteristics of the current DME treatments. Identifying specific criteria rather than using sets of generic criteria addresses and defines the health issue and the characteristics of the possible treatments more precisely without excluding any specific relevant criterion.

This analysis is not without limitations. In any analysis, the results are determined by the data available. In this sense, the weighting of the established criteria is subject to uncertainty, as it is influenced by the number of participating experts and, above all, by the proportion of those participants in each stakeholder group. The objective of the study was to provide a global perspective as an aid to decision-making in the treatment of DME, so the results from all stakeholder groups were included but they were aggregated to give the most representative multistakeholder perspective on DME treatment possible. However, it could be interesting to carry out a specific study to determine the criteria that were prioritized by each group of stakeholders. In addition, the prioritization of the criteria by each participant may have been influenced by their interpretation of the criteria included in the analysis and the levels included for each criterion. This interpretation would depend on the stakeholder group to which they belong and their familiarity with or knowledge of each criterion. To account for this, definitions of and information on the criteria were included in the questionnaires for each phase to aid participant understanding. MCDAs can be used to support health decision-making in multiple ways, for example in health planning and research, in the pricing and financing of health technologies, and in treatment selection [1, 2, 12]. According to the statistics reported in [12], more than half of all healthcare-related MCDAs have been performed to support decisions regarding health intervention reimbursement and coverage. Another frequent reason for applying MCDA in healthcare is to inform decisions regarding the selection or prioritization of treatments. The main areas in which MCDAs are applied are in the diagnosis and treatment of pathologies, prioritization policies, and the evaluation of health technologies [2]. MCDAs have been used by various public and private health technology assessment organizations and agencies in different countries [13], such as Germany [14], Norway [15], Italy [16], Australia [17], and Thailand [18, 19].

In our country, Spain, only a few MCDAs have been published in the field of healthcare [20–28], although the number of healthcare-related publications that incorporate MCDA is increasing in Spain and globally. To our knowledge, this is the first MCDA to be conducted on the management of DME as well as in the field of ophthalmology in Spain. The literature on the application of MCDA to DME or indeed ophthalmology in general is currently very limited. Recently in Italy, a MCDA was developed for the treatment of DME with the aim of complementing health technology assessment in several regions of the country [29–32]. This study included two phases: (a) the criteria were prioritized based on the general model from the European Network for Health Technology Assessment (EUnetHTA), and (b) each of the alternatives was scored according to its performance (which was assessed based on the previously prioritized criteria). One of the main differences of that study from the present work is that the former MCDA was developed according to the EVIDEM (Evidence and Value: Impact on Decision-Making) methodology, which involved comparative scoring of the alternatives and criteria prioritization using a direct classification method instead of a decompositional method such as a DCE. However, both studies found that safety criteria were assigned the highest priority, whereas efficacy was considered to be less of a priority than other criteria such as economic impact and general relevance. The results of that study concluded that, according to the perspectives of the stakeholders involved, dexamethasone could be the most advantageous treatment option, as it yielded the highest score based on the multiple criteria selected in the MCDA.

A MCDA that evaluated the most relevant health outcomes of opioid substitution treatment programs in patients with disorders resulting from opioid use was recently developed in Spain [21]. That study followed the same methodology as the present MCDA: the relevant criteria and their weights were established by identifying the preferences of experts through a DCE. The main differences of that study from the present analysis are that the aim of the former study was to evaluate exclusively health outcomes from a clinical perspective instead of including different stakeholders. One of the most interesting aspects of that study was that the analysis was conducted using different patient profiles, which led to different criteria weighting in each case.

Some MCDAs have been used in our country to compare alternative treatments for various pathologies, such as chronic dermatological inflammatory diseases, cancer, rare diseases, and cardiovascular diseases such as nonvalvular atrial fibrillation and pulmonary hypertension [24–26, 28]. Other applications of MCDA include the development of an assessment framework for rare diseases at a regional level in Catalonia [22] and the development of a decision-support tool for drug evaluation in a pharmacy and therapeutics committee setting at the hospital level [20]. MCDA was also used to establish an algorithm for predicting price and reimbursement decisions at national and regional levels [27]. Some studies have used the EVIDEM methodology to develop the analysis [20, 22–25, 28]. In those studies, the methods used to prioritize the criteria were fundamentally compositional, such as direct classification or the analytic hierarchical process [22–28]. Either a single-stakeholder perspective was used, such as that of patients [20, 21, 26] or evaluation agencies [22, 27], or a multidisciplinary...
5 Conclusions

According to the preferences of the multiple stakeholders involved, an appropriate DME treatment should guarantee the safety of the patient while maximizing improvements in their visual acuity for the longest effect duration. In addition, the DME treatment should have an affordable annual cost that contributes to the health system sustainability. Finally, it should have a positive impact on the health-related quality of life of the patient and prevent the onset or progression of disability.

Data Availability Statement The data that support the findings of this study are available on request from Pharmacoeconomics & Outcomes Research Iberia (PORIB), under the authorization of the data owner. The data are not publicly available due to restrictions related to confidentiality.

Compliance with Ethical Standards

Funding This project benefited from an unrestricted grant from Allergan, S.A.U.

Conflict of interest FdA-N and MAC are employees of PORIB, a consultancy firm specialized in health technology assessment, which received funding from Allergan S.A.U. for the development of this project. EA, EC, AGL, EI, IL, JMO, JMMS, MM, CM, PO, GP, JLP, MRM, JMRM, JLT, PU, JZV, and JZ received fees for their participation in this project.

Contributions FdA-N and MAC made substantial contributions to the conception and design of the work and the analysis and interpretation of data. EA, EC, AGL, EI, IL, JMO, JMMS, MM, CM, PO, GP, JLP, MRM, JMRM, JLT, PU, JZV, and JZ revised the manuscript. FdA-N and MAC made substantial contributions to the design of the work and the acquisition and interpretation of data. These authors were also participants in the study (members of the expert group during at least one of the phases of the study). FdA-N drafted the manuscript. MAC, EA, EC, AGL, EI, IL, JMO, JMMS, MM, CM, PO, GP, JLP, MRM, JMRM, JLT, PU, JZV, and JZ revised the manuscript. All of the authors approved the version to be published and agree to be accountable for all aspects of the work and to ensure that questions relating to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Guarantor Fernando de Andrés-Nogales.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Thokala P, Devlin N, Marsh K, et al. Multiple criteria decision analysis for health care decision making—an introduction: report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19:1–13.
2. Adunlin G, Diaby V, Xiao H. Application of multicriteria decision analysis in health care: a systematic review and bibliometric analysis. Health Expect. 2015;18:894–905.
3. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185–222.
4. Andonegu Nararro J, Jiménez Lasanta L. Diabetic macular edema. An Sist Sanit Navar. 2008;31(Suppl 3): 35–44 (in Spanish).
5. Romero-Aroca P. Targeting the pathophysiology of diabetic macular edema. Diabetes Care. 2010;33:2484–5.
6. Romero-Aroca P, de la Riva-Fernandez S, Valls-Mateu A, Sagarr-Alamo R, Moreno-Ribas A, Soler N. Changes observed in diabetic retinopathy: eight-year follow-up of a Spanish population. Br J Ophthalmol. 2016;100(10):1366–71.
7. Marsh K, Ijzerman M, Thokala P, ISPOR Task Force, et al. Multiple criteria decision analysis for health care decision making—emerging good practices: report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19:125–37.
8. Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14:403–13.
9. Reed Johnson F, Lanceras E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16:3–13.
10. Aizaki H. Basic functions for supporting an implementation of choice experiments in R. J Stat Soft Code Snippets. 2012;50:1–24.
11. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014. http://www.R-project.org. Accessed 10 Apr 2018.
12. Marsh K, Lanitis T, Neasham D, Orfano P, Caro J. Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature. Pharmacoeconomics. 2014;32:345–65.
13. Marsh K, Thokala P, Youngkong S, Chalkidou K. Incorporating MCDA into HTA: challenges and potential solutions, with a focus on lower income settings. Cost Eff Resour Alloc. 2018;16(Suppl 1):43.
14. Institute for Quality and Efficiency in Health Care. Choice-based conjoint analysis—pilot project to identify, weight, and prioritize multiple attributes in the indication “hepatitis C.” Version 1.1. Executive Summary of Working Paper No. GA10-03. Cologne: Institute for Quality and Efficiency in Health Care (IQWIG); 2014. https://www.iqwig.de/download/GA10-03_Executive-summary-of-working-paper-1.1_Conjoint-Analysis.pdf. Accessed 21 Dec 2018.
15. Defechereux T, Paolucci F, Mirelman A, et al. Health care priority setting in Norway a multicriteria decision analysis. BMC Health Serv Res. 2012;12:39.
16. Radaelli G, Lettieri E, Masella C, et al. Implementation of EUneHTA core model in Lombardy: the VTS framework. Int J Technol Assess Health Care. 2014;30:105–12.
17. Howard S, Scott IA, Ju H, McQueen L, Scaffull PA. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience. Aust Health Rev. 2018;43(5):591–9. https://doi.org/10.1071/AH18042.
18. Youngkong S, Baltussen R, Tantivess S, Mohara A, Teerawattananon Y. Multicriteria decision analysis for setting priorities for HIV/AIDS interventions in Thailand. Health Res Policy Syst. 2012;10:6.
19. Baños-Roldán Ú, Badia X, Marcos-Rodríguez JA, et al. Multicriteria decision analysis as a decision-support tool for drug evaluation: a pilot study in a Pharmacy and Therapeutics Committee setting. Int J Technol Assess Health Care. 2018;34:519–26.
20. Bobes J, Pascual F, Sabater E, et al. Análisis de decisión multicriterio en programas de tratamiento de sustitución de opiáceos en trastornos por consumo de opiáceos. Adicciones. 2018;30:167–9.
21. Gilabert-Perramon A, Torrent-Farnell J, Catalan A, et al. Drug evaluation and decision making in Catalonia: development and validation of a methodological framework based on multi-criteria decision analysis (MCDA) for orphan drugs. Int J Technol Assess Health Care. 2017;33:111–20.
22. Jiménez A, Ais A, Beaudet A, Gil A. Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA). Orphanet J Rare Dis. 2018;13:220.
23. Ferrario L, Foglia E, Bandello F, et al. A multi-criteria decision analysis approach within the diabetic macular edema field: the experience of 3 Italian regions. Value Health. 2016;19:A573.
24. Wagner M, Khoury H, Bennets L, et al. Appraising the value of lenvatinib for radio-iodine refractory differentiated thyroid cancer (Rr-Dtc): a multi-country study applying holistic multicriteria decision analysis (MCDA). Value Health. 2015;18:A477–8.
25. Wagner M, Samaha D, Cuervo J, et al. Applying reflective multicriteria decision analysis (MCDA) to patient–clinician shared decision-making on the management of gastroenteropancreatic neuroendocrine tumors (GEP-NET) in the Spanish context. Adv Ther. 2018;35:1215–31.
26. Weernink MGM, Vaanholt MCW, Groothuis-Oudshoorn CGM, et al. Patients’ priorities for oral anticoagulation therapy in non-valvular atrial fibrillation: a multi-criteria decision analysis. Am J Cardiovasc Drugs. 2018;18:493–502.
27. Williams P, Mauskopf J, Lebiecki J, Kilburg A. Using multicriteria decision analysis during drug development to predict reimbursement decisions. J Mark Access Health Policy. 2014;2:25270.
28. F. de Andrés-Nogales et al.
29. Wagner M, Sanabria D, Cuervo J, et al. Applying reflective multicriteria decision analysis (MCDA) to patient–clinician shared decision-making on the management of gastroenteropancreatic neuroendocrine tumors (GEP-NET) in the Spanish context. Adv Ther. 2018;35:1215–31.
30. Williams P, Mauskopf J, Lebiecki J, Kilburg A. Using multicriteria decision analysis during drug development to predict reimbursement decisions. J Mark Access Health Policy. 2014;2:25270.
31. Zozaya N, Martínez-Galdeano L, Alcalá B, et al. Determining the value of two biologic drugs for chronic inflammatory skin diseases: results of a multi-criteria decision analysis. Biodrugs. 2018;32:281–91.
32. Foglia E, Ferrario L, Zappini T, et al. L'impatto dell'introduzione di tecnologie innovative per l'edema maculare diabetico in Regione Veneto [The impact of introducing innovative technologies for diabetic macular edema in the Veneto Region]. E-Health. 2016;49:48–56.

Affiliations

Fernando de Andrés-Nogales1,2 · Miguel Ángel Casado1 · José Luis Trillo2 · José María Ruiz-Moreno3,4 · José Manuel Martínez-Sesmero5 · Gemma Peralta6 · José Luis Poveda7 · Pere Ortiz8 · Emilio Ignacio9 · Javier Zarranz-Ventura4,10 · Patricia Udaondo7 · Carlos Mur11 · Eloísa Álvarez5 · Enrique Cervera12 · Mercedes Martínez13 · Iñaki Llorente14 · Jacinto Zulueta15 · Mariano Rodriguez-Maqueda16 · Alfredo García-Layana6,17 · José Martínez-Olmos18

1 Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain
2 Departamento de Salud Clínico Malvarrosa, Valencia, Spain
3 Universidad Castilla La Mancha, Albacete, Spain; Vissum Corporación, Spain; Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain.
4 RETICS-OFTARED, Instituto de Salud Carlos III, Madrid, Spain
5 Hospital Clínico San Carlos, Madrid, Spain
6 Fundación Rosend Carrasco i Formiguera, MentBarcelona, Barcelona, Spain
7 Hospital Universitari i Politècnic La Fe, Valencia, Spain
8 Consorci MAR Parc de Salut de Barcelona, Barcelona, Spain
9 Universidad de Cádiz, Cádiz, Spain
10 Instituto Clinic de Oftalmologia, Hospital Clinic, Barcelona, Spain
11 Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain
12 Hospital General Universitario de Valencia, Valencia, Spain
13 Ministerio de Sanidad, Consumo y Bienestar Social, Madrid, Spain
14 Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain
15 Asociación Mácula Retina, Seville, Spain
16 Hospital Universitario Virgen del Rocío, Seville, Spain
17 Clínica Universitaria de Navarra, Pamplona, Spain
18 Senado de España, Madrid, Spain

\[\Delta\text{ Adis}\]